Pengaruh Faktor Risiko terhadap Kejadian Peningkatan Kadar Enzim Transaminase pada Pasien Covid-19 dengan Terapi Tocilizumab

Abstract: Tocilizumab is an anti-IL-6 which recommended as cytokine release syndrome therapy in the treatment of Covid-19. One side effects tocilizumab that can occur hepatotoxicity, from mild elevated transaminases to severe drug-induced liver injury (DILI). Currently, research related hepatotoxicity and risk factors affecting Covid-19 patients limited still needs conduct. This observational study with cross-sectional design. Data collection was carried out retrospectively using secondary data obtained medical records department, at Universitas Indonesia Hospital 2020-2021. Patients confirmed positive receiving record were included this study. Patient demographics, clinical diagnoses, laboratory examinations, history others medication also reviewed. less than 18 years old, incomplete data, referred other hospitals excluded. The sampling technique used total sampling, namely all who met inclusion criteria taken subject research. Chi-square test analyze relationship between each incidence transaminases. results showed several significantly increased given therapy, including age, obesity, diabetes mellitus, ceftriaxone antibiotic therapy.